Pemphigus in the XXI Century: New life to an old story

References

• Tron F, Gilbert D, Joly P, Mouquet H, Drouot L, Ayed MB, Sellami M, Masmoudi H, Makni S. Immunogenetics of pemphigus: An update. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Kawana S, Hashimoto T, Nishikawa T, Nishiyama S. Changes in clinical features, histologic findings, and antigen profiles with development of pemphigus foliaceus from pemphigus vulgaris. Arch Dermatol 1994; 130: 1534–1538
   PubMedGoogle Scholar
• Park SG, Chang JY, Cho YH, Kim SC, Lee MG. Transition from pemphigus foliaceus to pemphigus vulgaris: Case report with literature review. Yonsei Med J 2006; 47: 278–281
   PubMedGoogle Scholar
• Gniadecki R. Desmoglein autoimmunity in the pathogenesis of pemphigus. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Amagai M, Kitajima Y, Milner Y, Mahoney M, Gniadetski R, Ahmed AR, Bystryn J-C, Hertl M, Pincelli C, Grando SA. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just “witnesses of disease”?. Exp Dermatol 2006; 15: 815–831
   PubMed Web of Science ®Google Scholar
• Udey MC, Stanley JR. Pemphigus-diseases of antidesmosomal autoimmunity. JAMA 1999; 282: 572–576
   PubMed Web of Science ®Google Scholar
• Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000; 6: 1275–1277
   PubMed Web of Science ®Google Scholar
• Amagai M. Adhesion molecules. I: Keratinocyte–keratinocyte interactions; cadherins and pemphigus. J Invest Dermatol 1995; 104: 146–152
   PubMed Web of Science ®Google Scholar
• Caldelari R, de Bruin A, Baumann D, Suter MM, Bierkamp C, Balmer V, Muller E. A central role for the armadillo protein plakoglobin in the autoimmune disease pemphigus vulgaris. J Cell Biol 2001; 153: 823–834
   PubMed Web of Science ®Google Scholar
• Evangelista F, Dasher DA, Diaz LA, Li N. The prevalence of autoantibodies against E-cadherin in pemphigus. J Invest Dermatol 2006; 126(Suppl. 1)9
   Google Scholar
• Muller E, Caldelari R, De Bruin A, Baumann D, Bierkamp C, Balmer VV, Suter MM. Pathogenesis in pemphigus vulgaris: A central role for the armadillo protein plakoglobin. J Invest Dermatol 2000; 115: 332
   PubMedGoogle Scholar
• Calkins CC, Setzer SV, Jennings JM, Summers S, Tsunoda K, Amagai M, Kowalczyk AP. Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J Biol Chem 2006; 281: 7623–7634
   PubMed Web of Science ®Google Scholar
• Korman NJ, Eyre RW, Klaus-Kovtun V, Stanley JR. Demonstration of an adhering-junction molecule (plakoglobin) in the autoantigens of pemphigus foliaceus and pemphigus vulgaris. N Engl J Med 1989; 321: 631–635
   PubMed Web of Science ®Google Scholar
• Frusic-Zlotkin M, Raichenberg D, Wang X, David M, Michel B, Milner Y. Apoptotic mechanism in pemphigus autoimmunoglobulins-induced acantholysis: Possible involvement of the EGF receptor. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Kurzen H, Brenner S. Significance of autoimmunity to non-desmoglein targets in pemphigus. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Kurzen H, Henrich C, Booken D, Poenitz N, Gratchev A, Klemke CD, Engstner M, Goerdt S, Maas-Szabowski N. Functional characterization of the epidermal cholinergic system in vitro. J Invest Dermatol 2006;; 126: 2458–2472
   PubMed Web of Science ®Google Scholar
• Iraji F, Yoosefi A. Healing effect of Pilocarpine gel 4% on skin lesions of pemphigus vulgaris. Int J Dermatol 2006; 45: 743–746
   PubMed Web of Science ®Google Scholar
• Namazi MR. Practice pearl: Gargling with cholinergic ophthalmic drops for treating the oral lesions of pemphigus vulgaris. J Drugs Dermatol 2004; 3: 484–485
   Google Scholar
• Grando SA. New approaches to the treatment of pemphigus. J Invest Dermatol Symp Proc 2004; 9: 84–91
   PubMedGoogle Scholar
• Nguyen VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol 2004; 140: 327–334
   PubMed Web of Science ®Google Scholar
• Fimiani M, Rubegni P, Flori ML, De Aloe G, Andreassi L. Treatment of pemphigus senilis with tetracycline plus nicotinamide: Long term follow-up. J Am Ger Soc 1997; 45: 256–258
   PubMedGoogle Scholar
• Alpsoy E, Yilmaz E, Basaran E, Yazar S, Cetin L. Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus?. Arch Dermatol 1995; 131: 1339–1340
   PubMedGoogle Scholar
• Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: A review of 13 cases. J Am Acad Dermatol 1993; 28: 998–1000
   PubMed Web of Science ®Google Scholar
• Sawai T, Kitazawa K, Danno K, Sugie N, Machizuki T, Sugiura H, Uehara M. Pemphigus vegetans with oesophageal involvement: Successful treatment with minocycline and nicotinamide. Br J Dermatol 1995; 132: 668–670
   PubMed Web of Science ®Google Scholar
• Izu K, Yamamoto O, Masuyuki K, Asahi M, Komai R, Yasumoto S, Hashimoto T. A case of pemphigus foliaceus associated with bullous impetigo successfully treated with tetracycline and nicotinamide. J UOEH 2001; 23: 59–67
   PubMedGoogle Scholar
• Orlov MD, Chernyavsky AI, Arredondo J, Grando SA. Synergistic actions of pemphigus vulgaris IgG, Fas-ligand and tumor necrosis factor-α during induction of basal cell shrinkage and acantholysis. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Dick SE, Werth VP. Pemphigus: A treatment update. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Berthou C, Michel L, Soulie A, Jean-Louis F, Flageul B, Dubertret L, Sigaux F, Zhang Y, Sasportes M. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol 1997; 159: 5293–5300
   Google Scholar
• Viac J, Gueniche A, Doutremepuich JD, Reichert U, Claudy A, Schmitt D. Substance P and keratinocyte activation markers: An in vitro approach. Arch Dermatol Res 1996; 288: 85–90
   PubMed Web of Science ®Google Scholar
• Wang X, Bregegere F, Frusic-Zlotkin M, Feinmesser M, Michel B, Milner Y. Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins. Apoptosis 2004; 9: 131–143
   PubMed Web of Science ®Google Scholar
• Arredondo J, Chernyavsky AI, Karaouni A, Grando SA. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol 2005; 167: 1531–1544
   PubMed Web of Science ®Google Scholar
• Feliciani C, Toto P, Amerio P, Mohammad S, Coscione PS, Amerio P, Shivji G, Wang B, Sauder SN. In vitro and in vivo expression of interleukin-1α and tumor necrosis factor-α mRNA in pemphigus vulgaris: Interleukin-1α and tumor necrosis factor-α are involved in acantholysis. J Invest Dermatol 2000; 114: 71–77
   PubMed Web of Science ®Google Scholar
• Bhogal B, Wojnarowska F, Black MM, Xu W, Levene GM. The distribution of immunoglobulins and the C3 component of complement in multiple biopsies from the uninvolved and perilesional skin in pemphigus. Clin Exp Dermatol 1986; 11: 49–53
   PubMedGoogle Scholar
• Grando SA, Grando AA, Glukhenky BT, Doguzov V, Nguyen VT, Holubar K. History and clinical significance of mechanical symptoms in blistering dermatoses: A reappraisal. J Am Acad Dermatol 2003; 48: 86–92
   PubMed Web of Science ®Google Scholar
• Chernyavsky A, Grando SA. Characterization of novel signaling pathways downstream of non-desmoglein targets of pathogenic autoantibodies in pemphigus vulgaris. J Invest Dermatol 2006; 126: 2352
   Google Scholar
• Rubenstein DS, Diaz LA. Pemphigus antibody induced phosphorylation of keratinocyte proteins. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Berkowitz P, Hu P, Liu Z, Diaz LA, Enghild JJ, Chua MP, Rubenstein DS. Desmosome signaling: Inhibition of p38MAPK prevents pemphigus vulgaris IgG induced cytoskeleton reorganization. J Biol Chem 2005; 280: 23778–23784
   PubMed Web of Science ®Google Scholar
• Sanchez-Carpintero I, Espana A, Pelacho B, Moratalla LN, Rubenstein DS, Diaz LA, Lopez-Zabalza MJ. In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades. Br J Dermatol 2004; 151: 565–570
   PubMed Web of Science ®Google Scholar
• Williamson L, Raess NA, Caldelari R, Zakher A, de Bruin A, Posthaus H, Bolli R, Hunziker T, Suter MM, Muller EJ. Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin. EMBO J 2006; 25: 3298–3309
   PubMed Web of Science ®Google Scholar
• Kitajima Y. Current and prospective understanding of clinical classification, pathomechanisms and therapy in pemphigus. Arch Dermatol Res 2003; 295(Suppl. 1)S17–S23
   Google Scholar
• Kawasaki Y, Aoyama Y, Tsunoda K, Amagai M, Kitajima Y. Pathogenic monoclonal antibody against desmoglein 3 augments phosphorylation of desmoglein 3 and p38 MAPK in a human squamous carcinoma cell line. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Wang X, Bregegere F, Soroka Y, Frusic-Zlotkin M, Milner Y. Replicative senescence enhances apoptosis induced by pemphigus autoimmune antibodies in human keratinocytes. FEBS Lett 2004; 567: 281–286
   PubMed Web of Science ®Google Scholar
• Singer KH, Sawka NJ, Samowitz HR, Lazarus GS. Proteinase activation: A mechanism for cellular dyshesion in pemphigus. J Invest Dermatol 1980; 74: 363–367
   PubMedGoogle Scholar
• Morioka S, Naito K, Ogawa H. The pathogenic role of pemphigus antibodies and proteinase in epidermal acantholysis. J Invest Dermatol 1981; 76: 337–341
   PubMedGoogle Scholar
• Woo TY, Hogan VA, Patel H, Anhalt GJ, Labib RS, Voorhees JJ, Diaz LA. Specificity and inhibition of the epidermal cell detachment induced by pemphigus IgG in vitro. J Invest Dermatol 1983; 81: 115s–121s
   PubMedGoogle Scholar
• Naito K, Morioka S, Nakajima S, Ogawa H. Proteinase inhibitors block formation of pemphigus acantholysis in experimental models of neonatal mice and skin explants: Effects of synthetic and plasma proteinase inhibitors on pemphigus acantholysis. J Invest Dermatol 1989; 93: 173–177
   PubMedGoogle Scholar
• Hashimoto K, Wun TC, Baird J, Lazarus GS, Jensen PJ. Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor. J Invest Dermatol 1989; 92: 310–314
   PubMedGoogle Scholar
• Grando SA, Glukhen'kii BT, Romanenko AB. Role of endogenous proteinases and their inhibitors in the pathogenesis of pemphigus vulgaris (in Russian). Vestn Dermatol Venerol 1987; 8: 4–7
   Google Scholar
• Grando SA. Decompensation in proteinase-inhibitor system and application of proteinase inhibitors in pemphigus and pemphigoid. J Dermatol Sci 1992; 4: 95–97
   PubMedGoogle Scholar
• Mahoney MG, Wang ZH, Stanley JR. Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice. J Invest Dermatol 1999; 113: 22–25
   PubMed Web of Science ®Google Scholar
• Lanza A, Femiano F, De Rosa A, Cammarota M, Lanza M, Cirillo N. The N-terminal fraction of desmoglein 3 encompassing its immundominant domain is present in human serum: Implications for pemphigus vulgaris autoimmunity. Int J Immunopathol Pharmacol 2006; 19: 399–407
   PubMed Web of Science ®Google Scholar
• Grando SA. Cholinergic control of epidermal cohesion in norm and pathology. Exp Dermatol 2006; 15: 265–282
   PubMed Web of Science ®Google Scholar
• Rios-Doria J, Day KC, Kuefer R, Rashid MG, Chinnaiyan AM, Rubin MA, Day ML. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 2003; 278: 1372–1379
   PubMed Web of Science ®Google Scholar
• Weiske J, Huber O. Fate of desmosomal proteins in apoptotic epidermal cells. Methods Mol Biol 2005; 289: 175–192
   PubMedGoogle Scholar
• Struff WG, Klasser M, Eckert V, Dietrich RL. Safety monitoring of a polyvalent immunoglobulin preparation: Documentation of 15,548 administrations. Int J Clin Pharmacol Ther 2005; 43: 420–428
   PubMedGoogle Scholar
• Bystryn J-C, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Auerbach R, Bystryn JC. Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. Arch Dermatol 1979; 115: 728–730
   PubMedGoogle Scholar
• Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Grando SA, Drannik GN, Glukhenky BT, Kostromin AP, Romanenko AB, Chayun OA, Chernyavsky AI. Clinical and laboratory evaluation of hemocarboadsorption in autoimmune bullous dermatoses. Int J Artifl Org 1990; 13: 181–188
   PubMedGoogle Scholar
• Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Romanenko AB. The effect of experimental hemocarbofiltration upon activity of mononuclear cells from normal and autoimmune patients. Immunology 1989; 66: 138–142
   PubMed Web of Science ®Google Scholar
• Barchan D, Souroujon MC, Im SH, Antozzi C, Fuchs S. Antigen-specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit. Proc Natl Acad Sci USA 1999; 96: 8086–8091
   PubMed Web of Science ®Google Scholar
• Garcia G, Komagata Y, Slavin AJ, Maron R, Weiner HL. Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. J Autoimmun 1999; 13: 315–324
   PubMedGoogle Scholar
• Li HL, Liu JQ, Bai XF, vn der Meide PH, Link H. Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats. Immunology 1998; 94: 431–437
   PubMedGoogle Scholar
• Seissler J, Scherbaum WA. Autoimmune diagnostics in diabetes mellitus. Clin Chem Lab Med 2006; 44: 133–137
   PubMedGoogle Scholar
• Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869–877
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin—a novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 2000; 275: 29466–29476
   PubMed Web of Science ®Google Scholar
• Grando SA. Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology 2000; 201: 290–295
   PubMed Web of Science ®Google Scholar
• Amagai M, Ishii K, Hashimoto T, Gamou S, Shimizu N, Nishikawa T. Conformational epitopes of pemphigus antigens (Dsg1 and Dsg3) are calcium dependent and glycosylation independent. J Invest Dermatol 1995; 105: 243–247
   PubMed Web of Science ®Google Scholar
• Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59–67
   PubMed Web of Science ®Google Scholar
• Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992; 90: 919–926
   PubMed Web of Science ®Google Scholar
• Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y, Tsunoda K, Amagai M, Stanley JR, Siegel DL. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 2005; 115: 888–899
   PubMed Web of Science ®Google Scholar
• Tsunoda K, Ota T, Aoki M, Yamada T, Nagai T, Nakagawa T, Koyasu S, Nishikawa T, Amagai M. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 2003; 170: 2170–2178
   PubMed Web of Science ®Google Scholar
• Ding X, Aoki V, Mascaro JM, Jr, Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997; 109: 592–596
   PubMed Web of Science ®Google Scholar
• Ishii K, Harada R, Matsuo I, Shirakata Y, Hashimoto K, Amagai M. In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris. J Invest Dermatol 2005; 124: 939–946
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Tsunoda K, Hata T, Ishii K, Yamada T, Amagai M. Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation. J Invest Dermatol 2006, in press
   PubMedGoogle Scholar
• Nguyen VT, Lee TX, Ndoye A, Shultz LD, Pittelkow MR, Dahl MV, Lynch PJ, Grando SA. The pathophysiological significance of non-desmoglein targets of pemphigus autoimmunity. Pemphigus vulgaris and foliaceus patients develop antibodies against keratinocyte cholinergic receptors. Arch Dermatol 1998; 134: 971–980
   PubMedGoogle Scholar
• Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000; 106: 1467–1479
   PubMed Web of Science ®Google Scholar
• Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: Review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006; 39, this issue
   PubMedGoogle Scholar
• Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, Webber RJ, Pittelkow MR, Lynch PJ, Grando SA. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: A reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001; 137: 193–206
   PubMedGoogle Scholar
• Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie HD, Mutasim D, Ariss-Abdo L, Labib RS. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729–1735
   PubMed Web of Science ®Google Scholar